An unusual cause of cancer mimicry following liver transplantation

Autores: Qumosani Karim, Chandok Natasha

Resumen

Sirolimus is an approved anti-rejection agent following liver or kidney transplantation that works through inhibition of the mammalian target of rapamycin (mTOR). As sirolimus functions through a pathway independent of calcineurin inhibition, it may have less potential for nephrotoxicity and carcinogenesis. That being said, there are a myriad of potential adverse effects reported with sirolimus, many of which are severe and unknown or poorly understood. Herein we present a case of sirolimus causing a serious but uncommon adverse event in an adult liver transplant recipient; the adverse event in this instance unfortunately resulted in significant medical testing and morbidity. The adverse event profile of sirolimus is summarized through review of available evidence.

Palabras clave: Sirolimus rapamune neoplasm adverse drug event.

2011-11-29   |   521 visitas   |   Evalua este artículo 0 valoraciones

Vol. 11 Núm.1. Enero-Febrero 2012 Pags. 134-137 Ann Hepatol 2012; 11(1)